The Bundibugyo virus was first identified in Uganda in 2007. It is a distinct species from the more common Zaire ebolavirus, which caused the massive 2014–2016 West Africa epidemic. This distinction is critical for one urgent reason: there is no FDA-licensed or authorized vaccine and no approved specific treatment for Bundibugyo virus disease .
The existing Ebola vaccine, ERVEBO®, is only effective against the Zaire species and is not expected to protect against Bundibugyo virus . While the Bundibugyo strain is generally less lethal than Zaire — with a typical fatality rate of 30%–50% compared to 70%–90% — the absence of a pharmaceutical safety net makes containment extremely challenging
.
In response, the WHO is accelerating the preparation of clinical trials for experimental treatments and candidate vaccines. Its research advisory group has recommended prioritizing two monoclonal antibodies for evaluation . However, for now, the entire response relies on classic public health pillars.
The outbreak has not been contained within a single area, complicating control efforts.
With no medical countermeasures, contact tracing is the single most powerful tool to break chains of transmission. However, current efforts are falling short.
As of early June, over 500 contacts were being monitored in the DRC and over 100 in Uganda, but the proportion of listed contacts actually reached and tracked remains insufficient for effective containment . Another tracker reported that contact tracing in Ituri was at just 39.3%, far below the >90% coverage needed to stay ahead of the virus
. The massive number of suspected cases—906 compared to 381 confirmed—is a red flag indicating extensive undetected transmission in the community
.
The outbreak is also unfolding in a context of armed conflict, population displacement, and fragile health infrastructure in eastern DRC, all of which impede safe and timely contact tracing .
The United States moved swiftly to prevent the importation of cases.
Other countries and agencies have taken similar steps. The European Centre for Disease Prevention and Control (ECDC) has advised EU/EEA countries to review and update their isolation and contact-tracing procedures .
Amid the grim numbers, there is a sign that survival is possible even without a specific antiviral. On May 31, WHO Director-General Tedros Adhanom Ghebreyesus announced during a visit to Bunia, the capital of Ituri, that four nurses who had contracted Ebola had fully recovered and been discharged from the hospital . A laboratory worker had already been discharged days earlier, bringing the total number of recoveries in the DRC to five
.
This demonstrates that with early diagnosis and proactive supportive care—including fluid and electrolyte management and treatment of complications—patients can survive, even with no targeted drug to fight the virus . The WHO has since reported eight total patients discharged, including two from Uganda
. This outcome, however, has been offset by the toll on healthcare workers: the Africa CDC reports that 34 health workers have been infected in this outbreak, with 7 fatalities
.
The crisis is highly dynamic. Key indicators to follow include whether contact tracing rates improve toward the 90% threshold, the speed at which experimental vaccines enter clinical trials, and any further geographic spread both inside and outside the current affected countries. The WHO has requested $115 million over three months for the response, and as of early June, only 35% of that goal had been met, raising serious concerns about the sustainability of the international effort .
Comments
0 comments